Scripps Research

Name

Scripps Research

Legal name

The Scripps Research Institute

Website

https://scripps.edu

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Biomedical Research and Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Biomedical research
• Drug discovery
• Translational medicine
• Clinical therapeutics
• Regenerative medicine

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Licensing and Partnership Revenue: Scientific discoveries are turned into new medicines and partnered with pharmaceutical companies for further development. Licensing revenues generated from these partnerships are reinvested into research programs, creating a self-renewing funding source. Royalties from successful therapies can outpace returns of traditional endowments.
2. NIH and Federal Research Grants: Major federal funding including the $67M NIH CAMPP pandemic preparedness award, NIH Director's Transformative Research Award ($14.2M), and various NIH grants for HIV, global health, and other programs.
3. Philanthropy and Private Donations: As a registered 501(c)(3) nonprofit organization, Scripps Research relies on private support, applying the majority of each dollar contributed to research efforts. The Prebys Foundation provided a $7M emergency support package amid federal funding cuts.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Scripps Research is a nonprofit biomedical research institute that combines fundamental scientific discovery with translational drug development through its Calibr-Skaggs Institute for Innovative Medicines, advancing clinical-stage therapeutic candidates in infectious disease, regenerative medicine, and immunotherapy. It generates revenue primarily through licensing its drug candidates and platforms to pharmaceutical partners, federal research grants, and philanthropic donations.

Product overview

Scripps Research is a nonprofit biomedical research institute with two primary translational research divisions: the Calibr-Skaggs Institute for Innovative Medicines (nonprofit drug discovery hub) and the Scripps Research Translational Institute (individualized and digital medicine). The organization operates a diverse therapeutic pipeline spanning multiple technology platforms including switchable CAR-T cell therapies (sCAR-T), regenerative medicine programs (CMR316, CLF065, KA34), global health therapeutics (HIV, malaria, tuberculosis, COVID-19 antivirals), and neurological disease treatments (PDM608). Core enabling platforms include the ReFRAME drug repurposing library (~12,000 compounds), DNA-Encoded Library (DEL) for high-throughput screening, and a Long-Acting Drug Platform utilizing prodrug formulations, peptide stapling, and antibody fusions. The portfolio includes multiple clinical-stage candidates across oncology, regenerative medicine, infectious disease, and metabolic disorders.

Differentiator

Problem solved

Functional benefit

Brands

• Calibr-Skaggs Institute for Innovative Medicines: Nonprofit drug discovery hub and division of Scripps Research dedicated to translating groundbreaking scientific discoveries into therapeutic advances
• Scripps Research Translational Institute
• Skaggs Graduate School of Chemical and Biological Sciences
• Front Row Lecture Series

Products and services

• Calibr-Skaggs Institute for Innovative Medicines Integrated translational drug discovery engine within Scripps Research that advances small molecules, biologics, and cell therapies from concept to clinical-stage candidates, offered to pharmaceutical partners via licensing and co-development deals.
• ReFRAME Drug Repurposing Library The world's most comprehensive drug repurposing collection, assembled and maintained by Scripps Research, used by external researchers to rapidly identify existing drugs with potential activity against priority diseases including COVID-19 and tuberculosis.
• sCAR-T Cell Therapy Program Switchable CAR-T (sCAR-T) cell therapy platform developed by Scripps Research that enables controllable, tunable activity of engineered T cells for cancer immunotherapy, with candidates advancing toward clinical use.
• Long-Acting Drug Delivery Platform Proprietary drug delivery technology developed at Scripps Research that extends the half-life and dosing intervals of therapeutics, applied to long-acting formulations such as the institute's HIV pre-exposure prophylaxis candidates.
• DNA-Encoded Library (DEL) Screening DNA-encoded library-based screening service operated by Scripps Research to identify chemical starting points for drug discovery against biologically validated targets, available via collaboration and partnership.
• Skaggs Graduate School for Chemical and Biological Sciences Fully funded PhD graduate program at Scripps Research that trains doctoral students in chemical and biological sciences through research in institute faculty laboratories.
• Heart Regeneration Program Translational research program at Scripps Research developing cell-based regenerative therapies to repair heart tissue damaged by myocardial infarction and other cardiac injuries.
• Hematopoietic Stem Cell Differentiation Program Translational program at Scripps Research that develops methods to differentiate hematopoietic stem cells into functional blood and immune cells for therapeutic use in hematologic and immunologic diseases.
• Scripps Research Translational Institute (SRTI) Translational medicine program at Scripps Research that combines genomics, digital health, and clinical research to advance precision and preventive medicine, including the NIH-backed All of Us research program work.
• Clinical-Stage Drug Candidates (CMR215, CMR316, CLF065, KA34, PDM608, CMZ371, CLB073, CBE161, CLZ629) Licensable clinical-stage drug candidates developed at Scripps Research including Mpro inhibitors for COVID-19 (CMR316), antimalarials, TB therapeutics, and other assets, available to pharmaceutical partners via licensing and co-development.

Quantifiable outcome

• 15 FDA-approved medications developed by Scripps Research scientists
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

18 partnerships are on record, tiered core and minor.

• UC San DiegocoreStrategic or Co-development Partner · 22 June 2026Researchers at Scripps Research collaborated with UC San Diego and Lowy Medical Research Institute to discover erucamide's protective role in the retina, potentially offering a new approach to slowing vision loss from degenerative diseases.
• Dyadic InternationalcoreStrategic or Co-development Partner · 15 June 2026Partnership with Dyadic International for vaccine and antibody development using the C1 protein production platform, enabling rapid progression from gene sequence to purified antigen or antibody in approximately 15 days for infectious disease threats.
• Dyadic InternationalcoreStrategic or Co-development Partner · 28 May 2026Dyadic International and Scripps Research collaborate on developing monoclonal antibody and vaccine candidates targeting hantaviruses (including Andes virus causing Hantavirus Pulmonary Syndrome) using Dyadic's proprietary C1 microbial fungal-based protein production platform. The partnership builds on prior Andes virus, Marburg, and Ebola antibody work, aiming to address manufacturing bottlenecks exposed by COVID-19 and create opportunities in pandemic preparedness programs.
• Salk InstitutecoreStrategic or Co-development Partner · 7 April 2026Scripps Research is a collaborating institution in the ARPA-H-funded sonogenetics project led by the Salk Institute (up to $41.3M), developing ultrasound-sensitive proteins and wearable delivery systems for noninvasive cellular control. Scripps Research contributes expertise toward translating sonogenetics into clinical applications for conditions like peripheral neuropathy.
• KainomyxcoreStrategic or Co-development Partner · 17 February 2026Calibr-Skaggs and Kainomyx launched a collaboration to pioneer novel malaria treatments, combining Calibr's drug discovery capabilities with Kainomyx's specialized expertise.
• UC San DiegominorStrategic or Co-development Partner · 8 January 2026The San Diego County wastewater infectious disease surveillance system originated from academic research by UC San Diego and Scripps Research during the COVID-19 pandemic, with Scripps Research contributing expertise in pathogen detection and genomic sequencing.
• Allen InstitutecoreStrategic or Co-development Partner · 13 October 2025Scripps Research and the Allen Institute were awarded a $14.2 million NIH Director's Transformative Research Award to develop the first comprehensive atlas of the body's interoceptive neural network, led by Nobel laureate Ardem Patapoutian.
• ViomeminorStrategic or Co-development Partner · 15 July 2025Viome and Scripps Research announced a collaboration to develop a test for detecting precancerous colon polyps, leveraging Scripps Research's digital trials and translational medicine capabilities.
• Uvax BiocoreOEM/ Whitelabel/ Licensing Partner · 23 March 2025CEPI invested up to $2.6 million in Uvax Bio to advance its MERS coronavirus vaccine using Scripps Research's proprietary 1c-SApNP nanoparticle technology licensed from Scripps Research. The technology mimics the size and shape of the virus to trigger enhanced immune responses.
• OuraminorStrategic or Co-development Partner · 27 February 2025Oura and Scripps Research Digital Trials Center collaborate on a first-of-its-kind pregnancy study analyzing biobehavioral changes during pregnancy, aiming to identify warning signs of postpartum depression, miscarriage risk, and pre-term labor through biometric data from Oura Ring.
• IAVIcoreStrategic or Co-development Partner · 1 January 2025Scripps Research scientists contribute to IAVI's HIV vaccine clinical trials (IAVI G002 and G003), testing mRNA-based stepwise vaccination strategies to guide the immune system toward broadly neutralizing antibodies against HIV. Phase 1 trials showed strong VRC01-class antibody responses.
• AbbViecoreStrategic or Co-development Partner · 6 February 2024AbbVie and Calibr-Skaggs expanded their strategic collaboration to develop several preclinical and early-stage clinical assets. AbbVie also collaborated with Scripps Research on COVID-19 antiviral treatments. The sCAR-T program (CLBR001 + SWI019) is partnered with AbbVie for B-cell lymphomas and autoimmune diseases.
• GileadcoreOEM/ Whitelabel/ Licensing Partner · 4 January 2024Calibr announced a license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir, leveraging Calibr-Skaggs' long-acting injectable platform.
• Bill & Melinda Gates Medical Research InstitutecoreStrategic or Co-development Partner · 15 February 2023Calibr-Skaggs and Bill & Melinda Gates Medical Research Institute announced a licensing agreement for a novel candidate tuberculosis treatment compound (CLB073/TBD11), part of efforts to shorten TB therapy duration.
• AbbViecoreStrategic or Co-development Partner · 15 March 2022AbbVie and Scripps Research announced a collaboration to develop antiviral treatments for COVID-19, leveraging Scripps Research's expertise in structure-based drug design and Calibr-Skaggs' drug discovery capabilities.
• AbbViecoreStrategic or Co-development Partner · 9 December 2019Scripps Research and AbbVie announced a collaboration to develop a broad range of new therapeutics, marking the beginning of their strategic partnership that has since expanded across multiple therapeutic areas.
• Model MedicinesminorStrategic or Co-development PartnerModel Medicines conducted preclinical studies at Scripps Research for its broad-spectrum antiviral candidate MDL-001, demonstrating equivalence to sofosbuvir in HCV treatment. IND-enabling studies are ongoing with regulatory submission targeted for 2026.
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development PartnerCalibr-Skaggs partners with MMV on malaria drug development, including CBE161 (MMV371) for seasonal malaria prevention with once-every-2-month intramuscular injectable dosing to improve compliance.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Salk Institute for Biological Studies: A neighboring nonprofit biomedical research institute also located in La Jolla, California, conducting fundamental and translational research with a comparable faculty-driven model and similar funding structure (federal grants, philanthropy, partnerships).
• Howard Hughes Medical Institute (HHMI): A large nonprofit biomedical research organization that funds investigator-led science at universities and institutes, including HHMI Investigators at Scripps Research itself. Operates a comparable model of supporting top-tier scientists pursuing high-risk, high-reward research.
• Broad Institute of MIT and Harvard: A nonprofit biomedical and genomic research institute with a similar integrated model of basic science, translational research, and industry partnerships. Comparable in scale of faculty, funding, and mission to translate discovery into medicine.
• Whitehead Institute for Biomedical Research: A nonprofit, independent research institute affiliated with MIT that focuses on fundamental biomedical research and translational science, comparable in faculty size, nonprofit status, and mission to advance human health through discovery.
• Gladstone Institutes: An independent nonprofit life science research organization affiliated with UCSF that operates a similar model of combining basic science with translational and disease-focused research, and shares comparable funding mix of NIH grants and philanthropy.
• Allen Institute: A nonprofit research organization that operates large-scale research programs across neuroscience, immunology, and cell biology. Directly partnered with Scripps on the NIH Transformative Research Award and shares the nonprofit, project-based research model.
• Fred Hutchinson Cancer Center: A nonprofit research institution focused on cancer, infectious disease, and translational science with similar mechanisms of federal funding, philanthropy, and industry partnerships, and overlapping therapeutic areas with Scripps Research.
• Jackson Laboratory: An independent nonprofit biomedical research institute focused on genetics, genomics, and disease modeling, with comparable funding mechanisms (federal grants, philanthropy, fee-for-service) and a mission to translate basic science into medical advances.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: A larger, established cancer-focused research and treatment institution with deep translational capabilities and significant NIH funding. Comparable in mission to advance cancer therapeutics, though much larger in scope and resources than Scripps Research.

Emerging players

• Institute for Protein Design (University of Washington): A research institute at UW focused on computational protein design and synthetic biology. Comparable to Scripps Research's protein engineering and expanded genetic code work, though operating on a smaller scale and as a university unit rather than independent nonprofit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/scrippsresearch
• YouTubeyoutube.com/user/ScrippsResearch
• Facebookfacebook.com/ScrippsResearchInstitute
• LinkedInlinkedin.com/company/the-scripps-research-institute
• Instagraminstagram.com/scrippsresearch
• TikToktiktok.com/@scrippsresearch

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scripps Research